Although drug-eluting stents are known to reduce the risk of reste-nosis, and hence the need for reintervention, in patients at high risk of 11 restenosis enrolled in randomised clinical trials, there is little 'real-life' data currently available. The COMPARE study (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) aimed to compare the safety and efficacy of second-generation everolimus and paclitaxel-eluting stents in real-life practice.rnOne thousand eight hundred patients were randomly assigned to treatment with either a Xience Vor a Taxus Liberte stent in a 1:1 ratio. Patients were unaware of which stent they had been assigned to. The primary endpoint was a composite of safety and efficacy (all cause-mortality, myocardial infarction, and target vessel revascularisation) within 12 months.
展开▼
机译:尽管已知药物洗脱支架可降低再狭窄的风险,从而减少再干预的需要,但在随机临床试验中招募的患有11次再狭窄的高风险患者中,目前几乎没有“现实生活”数据。 COMPARE研究(在现实生活中使用第二代依维莫司洗脱支架和紫杉醇洗脱支架)旨在比较现实生活中第二代依维莫司和紫杉醇洗脱支架的安全性和有效性。1800名患者以1:1比例随机分配给Xience Vor Taxus Liberte支架治疗。患者不知道他们被分配到了哪个支架。主要终点是12个月内安全性和有效性(所有原因死亡,心肌梗死和目标血管血运重建)的综合指标。
展开▼